A股異動丨凱萊英(002821.SZ)漲4.27% 引入高瓴資本作為戰投 並與其簽署戰略合作協議
格隆匯5月13日丨凱萊英(002821.SZ)漲4.27%,報195.97元,總市值453.44億元。凱萊英今日早間公告,公司擬根據本次非公開發行股票的方案,引入高瓴資本管理有限公司作為戰略投資者,並與其簽署附條件生效戰略合作協議。本次非公開發行股票的價格為123.56元/股,高瓴資本認購金額不超過23.11億元。高瓴資本通過推動高瓴被投企業與公司建立合作關係,以及通過行業內的資源網絡推動製藥公司與公司建立合作關係,在本協議生效後的戰略合作期內,為公司帶來訂單累計不低於8億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.